Cargando…

Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls

Background: Heart failure with preserved ejection fraction (HFpEF) remains an ongoing therapeutic and diagnostic challenge to date. In this study we aimed for an analysis of the diagnostic potential of four novel cardiovascular biomarkers, GDF-15, H-FABP, sST2, and suPAR in HFpEF patients compared t...

Descripción completa

Detalles Bibliográficos
Autores principales: Jirak, Peter, Pistulli, Rudin, Lichtenauer, Michael, Wernly, Bernhard, Paar, Vera, Motloch, Lukas J., Rezar, Richard, Jung, Christian, Hoppe, Uta C., Schulze, P. Christian, Kretzschmar, Daniel, Braun-Dullaeus, Rüdiger C., Bekfani, Tarek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230638/
https://www.ncbi.nlm.nih.gov/pubmed/32326570
http://dx.doi.org/10.3390/jcm9041130
_version_ 1783535001453723648
author Jirak, Peter
Pistulli, Rudin
Lichtenauer, Michael
Wernly, Bernhard
Paar, Vera
Motloch, Lukas J.
Rezar, Richard
Jung, Christian
Hoppe, Uta C.
Schulze, P. Christian
Kretzschmar, Daniel
Braun-Dullaeus, Rüdiger C.
Bekfani, Tarek
author_facet Jirak, Peter
Pistulli, Rudin
Lichtenauer, Michael
Wernly, Bernhard
Paar, Vera
Motloch, Lukas J.
Rezar, Richard
Jung, Christian
Hoppe, Uta C.
Schulze, P. Christian
Kretzschmar, Daniel
Braun-Dullaeus, Rüdiger C.
Bekfani, Tarek
author_sort Jirak, Peter
collection PubMed
description Background: Heart failure with preserved ejection fraction (HFpEF) remains an ongoing therapeutic and diagnostic challenge to date. In this study we aimed for an analysis of the diagnostic potential of four novel cardiovascular biomarkers, GDF-15, H-FABP, sST2, and suPAR in HFpEF patients compared to controls as well as ICM, and DCM. Methods: In total, we included 252 stable outpatients and controls (77 DCM, 62 ICM, 18 HFpEF, and 95 controls) in the present study. All patients were in a non-decompensated state and on a stable treatment regimen. Serum samples were obtained and analyzed for GDF-15 (inflammation, remodeling), H-FABP (ischemia and subclinical ischemia), sST2 (inflammation, remodeling) and suPAR (inflammation, remodeling) by means of ELISA. Results: A significant elevation of GDF-15 was found for all heart failure entities compared to controls (p < 0.005). Similarly, H-FABP evidenced a significant elevation in all heart failure entities compared to the control group (p < 0.0001). Levels of sST2 were significantly elevated in ICM and DCM patients compared to the control group and HFpEF patients (p < 0.0001). Regarding suPAR, a significant elevation in ICM and DCM patients compared to the control group (p < 0.0001) and HFpEF patients (p < 0.01) was observed. An AUC analysis identified H-FABP (0.792, 95% CI 0.713–0.870) and GDF-15 (0.787, 95% CI 0.696–0.878) as paramount diagnostic biomarkers for HFpEF patients. Conclusion: Based on their differences in secretion patterns, novel cardiovascular biomarkers might represent a promising diagnostic tool for HFpEF in the future.
format Online
Article
Text
id pubmed-7230638
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72306382020-05-22 Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls Jirak, Peter Pistulli, Rudin Lichtenauer, Michael Wernly, Bernhard Paar, Vera Motloch, Lukas J. Rezar, Richard Jung, Christian Hoppe, Uta C. Schulze, P. Christian Kretzschmar, Daniel Braun-Dullaeus, Rüdiger C. Bekfani, Tarek J Clin Med Article Background: Heart failure with preserved ejection fraction (HFpEF) remains an ongoing therapeutic and diagnostic challenge to date. In this study we aimed for an analysis of the diagnostic potential of four novel cardiovascular biomarkers, GDF-15, H-FABP, sST2, and suPAR in HFpEF patients compared to controls as well as ICM, and DCM. Methods: In total, we included 252 stable outpatients and controls (77 DCM, 62 ICM, 18 HFpEF, and 95 controls) in the present study. All patients were in a non-decompensated state and on a stable treatment regimen. Serum samples were obtained and analyzed for GDF-15 (inflammation, remodeling), H-FABP (ischemia and subclinical ischemia), sST2 (inflammation, remodeling) and suPAR (inflammation, remodeling) by means of ELISA. Results: A significant elevation of GDF-15 was found for all heart failure entities compared to controls (p < 0.005). Similarly, H-FABP evidenced a significant elevation in all heart failure entities compared to the control group (p < 0.0001). Levels of sST2 were significantly elevated in ICM and DCM patients compared to the control group and HFpEF patients (p < 0.0001). Regarding suPAR, a significant elevation in ICM and DCM patients compared to the control group (p < 0.0001) and HFpEF patients (p < 0.01) was observed. An AUC analysis identified H-FABP (0.792, 95% CI 0.713–0.870) and GDF-15 (0.787, 95% CI 0.696–0.878) as paramount diagnostic biomarkers for HFpEF patients. Conclusion: Based on their differences in secretion patterns, novel cardiovascular biomarkers might represent a promising diagnostic tool for HFpEF in the future. MDPI 2020-04-15 /pmc/articles/PMC7230638/ /pubmed/32326570 http://dx.doi.org/10.3390/jcm9041130 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jirak, Peter
Pistulli, Rudin
Lichtenauer, Michael
Wernly, Bernhard
Paar, Vera
Motloch, Lukas J.
Rezar, Richard
Jung, Christian
Hoppe, Uta C.
Schulze, P. Christian
Kretzschmar, Daniel
Braun-Dullaeus, Rüdiger C.
Bekfani, Tarek
Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls
title Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls
title_full Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls
title_fullStr Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls
title_full_unstemmed Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls
title_short Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls
title_sort expression of the novel cardiac biomarkers sst2, gdf-15, supar, and h-fabp in hfpef patients compared to icm, dcm, and controls
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230638/
https://www.ncbi.nlm.nih.gov/pubmed/32326570
http://dx.doi.org/10.3390/jcm9041130
work_keys_str_mv AT jirakpeter expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols
AT pistullirudin expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols
AT lichtenauermichael expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols
AT wernlybernhard expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols
AT paarvera expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols
AT motlochlukasj expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols
AT rezarrichard expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols
AT jungchristian expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols
AT hoppeutac expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols
AT schulzepchristian expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols
AT kretzschmardaniel expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols
AT braundullaeusrudigerc expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols
AT bekfanitarek expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols